Insuline Medical Ltd
Yaad Sihan Projects Management and Entrepreneurship Ltd. is headquartered in Jerusalem, Israel.
Insuline Medical Ltd (INSL) - Net Assets
Latest net assets as of December 2017: ILA-63.00K ILA
Based on the latest financial reports, Insuline Medical Ltd (INSL) has net assets worth ILA-63.00K ILA as of December 2017.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA1.58 Million) and total liabilities (ILA1.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA-63.00K |
| % of Total Assets | -3.99% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 417.48 |
Insuline Medical Ltd - Net Assets Trend (2013–2017)
This chart illustrates how Insuline Medical Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Insuline Medical Ltd (2013–2017)
The table below shows the annual net assets of Insuline Medical Ltd from 2013 to 2017.
| Year | Net Assets | Change |
|---|---|---|
| 2017-12-31 | ILA-63.00K | +95.74% |
| 2016-12-31 | ILA-1.48 Million | -931.46% |
| 2015-12-31 | ILA178.00K | -96.51% |
| 2014-12-31 | ILA5.09 Million | +325.35% |
| 2013-12-31 | ILA-2.26 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Insuline Medical Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7906600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2017)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ILA1.83 Million | % |
| Other Components | ILA169.14 Million | % |
| Total Equity | ILA-63.00K | 100.00% |
Insuline Medical Ltd Competitors by Market Cap
The table below lists competitors of Insuline Medical Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AIR CHINA -H-
BE:AD2
|
$7.12K |
|
Staige One AG
XETRA:SPC
|
$7.12K |
|
Sharing Services Global Corp
PINK:SHRG
|
$7.12K |
|
XINHUA PHARMA -H- (XIN.SG)
STU:XIN
|
$7.13K |
|
Forward Science Corp.
TWO:7530
|
$7.10K |
|
PETZ3F
SA:PETZ3F
|
$7.10K |
|
Sipup Corporation
PINK:SPUP
|
$7.10K |
|
Colefax Group
LSE:CFX
|
$7.10K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Insuline Medical Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2016 to 2017, total equity changed from -1,480,000 to -63,000, a change of 1,417,000.
- Net loss of 7,014,000 reduced equity.
- Share repurchases of 7,938,000 reduced equity.
- Other factors increased equity by 16,369,000.
Equity Change Factors (2016 to 2017)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-7.01 Million | -11133.33% |
| Share Repurchases | ILA7.94 Million | -12600.0% |
| Other Changes | ILA16.37 Million | +25982.54% |
| Total Change | ILA- | % |
Book Value vs Market Value Analysis
This analysis compares Insuline Medical Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Insuline Medical Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -17535.00%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-1957.36%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | -23368.60% | 0.01x | 0.00x | ILA-28.05 Million |
| 2014 | -929.49% | -8290.54% | 0.04x | 2.72x | ILA-47.85 Million |
| 2015 | -8857.30% | -8085.13% | 0.02x | 47.80x | ILA-15.78 Million |
| 2016 | 0.00% | -10779.52% | 0.01x | 0.00x | ILA-8.80 Million |
| 2017 | 0.00% | -17535.00% | 0.03x | 0.00x | ILA-7.01 Million |
Industry Comparison
This section compares Insuline Medical Ltd's net assets metrics with peer companies in the Other industry.
Industry Context
- Industry: Other
- Average net assets among peers: $39,925,333
- Average return on equity (ROE) among peers: -29.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Insuline Medical Ltd (INSL) | ILA-63.00K | 0.00% | N/A | $7.11K |
| Biomedix Incubator Ltd (BMDX) | $22.00 Million | -65.28% | 0.03x | $127.40K |
| Black Sea Property PLC Ordinary Shares (BSP) | $1.91 Million | -202.26% | 1.13x | $59.37K |
| Ai Conversation Systems Ltd (FVT) | $22.19 Million | 66.99% | 2.97x | $8.00K |
| Gamatronic Electronic Industries Ltd (GAMT) | $108.08 Million | 0.13% | 0.24x | $38.38K |
| Panaxia Labs Israel Ltd (HROD) | $12.92 Million | -39.72% | 1.29x | $112.83K |
| The Israel Land Development Company Ltd (ILDA) | $21.85 Million | -30.46% | 0.50x | $30.98K |
| Itay Financial A.A Investments Ltd (ITYF) | $20.94 Million | 32.06% | 24.49x | $10.58K |
| Micronet Ltd (MCRNL) | $62.64 Million | -1.68% | 0.65x | $13.95K |
| Netz Hotels Ltd (NZHT) | $86.81 Million | -22.84% | 0.00x | $1.52K |